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ABSTRACT: Nowadays, tumor hypoxia has become a more
predominant problem for diagnosis as well as treatment of
cancer due to diﬃculties in delivering chemotherapeutic drugs
and their carriers to these regions with reduced vasculature and
oxygen supply. In such cases, external physical stimulus-
mediated drug delivery, such as ultrasound and magnetic ﬁelds,
would be eﬀective. In this work, the eﬀect of simultaneous
exposure of low-intensity pulsed ultrasound and static
magnetic ﬁeld on colon (HCT116) and hepatocellular
(HepG2) carcinoma cell inhibition was assessed in vitro.
The treatment, in the presence of anticancer drug, with and
without magnetic carrier, signiﬁcantly increased the reactive
oxygen species production and hyperpolarized the cancer cells.
As a result, a signiﬁcant increase in cell inhibition, up to 86%, was observed compared to 50% inhibition with bare anticancer
drug. The treatment appears to have relatively more eﬀect on HepG2 cells during the initial 24 h than on HCT116 cells. The
proposed treatment was also found to reduce cancer cell necrosis and did not show any inhibitory eﬀect on healthy cells
(MC3T3). Our in vitro results suggest that this approach has strong application potential to treat cancer at lower drug dosage to
achieve similar inhibition and can reduce health risks associated with drugs.
1. INTRODUCTION
In general, around the tumor environment, highly proliferating
mass of cells cause oxygen deﬁciency,1 leading to the formation
of hypoxic zones, which are diﬃcult to penetrate by the
standard chemotherapeutic or anticancer drugs due to reduced
vascular structure.2 Similarly, radiotherapy is also ineﬀective to
treat tumors with deoxygenated regions, as molecular oxygen is
essential to achieve the desired biological eﬀect of ionizing
radiation on cancer.3 Hypoxia is also known to eﬀect tumor cell
division and invasion (autonomous functions) and non-
autonomous processes, such as angiogenesis, lymph angio-
genesis, and inﬂammation, which are observed during meta-
stasis.4 Therefore, researchers developed a magnetic ﬁeld-
assisted treatment, where the drug-loaded vehicles are guided
and delivered to the hypoxic regions of the tumor using
external magnetic ﬁelds. External magnetic ﬁelds are also being
used to trigger the release of drug from the magnetic carrier at
the tumor site.5 Surface-modiﬁed microbubbles, triggered by
external ultrasound (US), have also been used to treat the
hypoxic zone of human breast cancer. The potential application
of such ultrasound-triggered oxygen delivery to solid tumors
improved the condition of tumor within 30 days.6 The potential
of this approach in targeting brain tumor using magnetic drug
carriers has also been demonstrated.7,8 Magnetic nanoparticles
(MNP) have been extensively used for various biomedical
applications including cancer.8 Ferromagnetic nanoparticles
(NPs) become magnetized under externally applied magnetic
ﬁelds and can easily agglomerate even in the absence of
magnetic ﬁelds. However, the use of paramagnetic or weakly
ferromagnetic NPs can eliminate this problem as they do not
exhibit magnetization in the absence of externally applied
magnetic ﬁelds.9 Therefore, paramagnetic or weakly ferromag-
netic NPs can be easily dispersed by magnetic ﬁeld for uptake
of phagocytes and increasing their half-life in the circulation.10
An important variant of magnetic ﬁeld-based cancer
treatment involves hyperthermia using MNP,11 where extreme
temperature elevation in the tumor cells (>40 °C) leads to
denaturation of the cellular protein and cellular death.
However, the use of MNP as drug-delivery system (DDS) is
associated with issues such as diﬃculties in measuring dose
concentration, dose dumping, and restricted range of hyper-
thermia.12 Accumulation of MNP also eﬀects their biological
response as DDS leads to rapid clearance of MNP from cells;13
therefore, high concentration of MNP is required to achieve the
desired therapeutic outcome. According to the literature,
minimum concentration of MNP required for eﬀective
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hyperthermia is between 1 and 2 mol/kg body mass, which is
signiﬁcantly higher than the concentration required for
magnetic resonance imaging and can eﬀect nearby healthy
tissues.14 More importantly, after repeated hyperthermia, the
cells were found to exhibit thermoresistance again and therefore
the treatment eﬃcacy decreases.15 On the other hand, external
magnetic ﬁelds have been used to avoid agglomeration and
accumulation of MNP, which can lead to local toxicity.16
In general, the use of static magnetic ﬁelds (SMF) as
adjuvant therapy toward cancer treatment has shown some
promising results in animal studies.17−20 SMF increased the
oxidative stress leading to cellular membrane damage and
apoptosis in cancer cells.21 Moreover, the interaction between
the SMF (200−2000 mT) and polar, ionic molecules of the
cancer cellular compartment can also generate reactive oxygen
species (ROS)22 and thus inhibit their growth. ROS
production23 is also found to damage the ion channels of
cancer cells, leading to changes in their morphology and
apoptosis. The application of SMF along with anticancer drug
improved the drug eﬃcacy and can eliminate the probability of
scar formation and infection.24 In myelogenous leukemia
(K562) cells, the use of 8.8 mT SMF eﬀectively enhanced
the potencies of various drugs (cisplatin, taxol, doxorubicin
(DOX), and cyclophosphamide).25 Large apophyses of 0.47
μm diameter and irregular apophyses (1.85 and 2.04 μm in
diameter) were formed with SMF application, which triggered
the uptake of anticancer drug and enhanced the potency of
these drugs.26 It appears that the use of SMF is eﬀective in
addressing the thermoresistance of cancer cells to repeated
hyperthermia and high concentration of MNP required to
create eﬀective hyperthermia.
Another important noninvasive cancer treatment approach is
ultrasound (US)-mediated targeted drug delivery,27 which
depends on mechanical eﬀects to induce stress response and
apoptosis in several cancer cell lines.28−31 US-assisted cancer
treatment eﬀectively enhanced cancer cell inhibition or death in
the presence of drugs and DDS.32−36 Typically, US creates
acoustic waves within the biological soft tissues through
nonthermal physical mechanisms that produce molecular
vibration in the tissue, resulting in mechanical stimulation to
accelerate membrane potential changes.37 Among diﬀerent
types of US, low-intensity pulsed ultrasound (LIPUS) was
found to alter cellular membrane properties in damaged or
diseased cells without eﬀecting the normal cells.38 Human
uterine sarcoma cell line (FU-MMT-3) treated with LIPUS (1
MHz, 2 W/cm2, 50% duty cycle, 60 s) in the presence of
irinotecan (CPT-11) and SN3838 showed VEGF inhibition.
Similarly, the eﬀectiveness of doxorubicin (DOX) on human
primary liver cancer cells has been enhanced with the
application of LIPUS.39
Nonetheless, the concept of utilizing SMF along with LIPUS
to facilitate enhanced drug delivery is not reported yet. In this
investigation, we have examined the use of SMF in the presence
of LIPUS, which can create Lorentz force on the cells/tissues,22
that rapidly oscillates the cells/ions/tissue and generates local
electrical currents/ﬁelds.22 Since the endogenous electrical
ﬁelds, present in the extracellular milieu, inﬂuence the cell
behavior,40 the SMF + LIPUS-generated in situ ﬁelds can also
inﬂuence cellular membrane, nucleus,41 etc. Some investigators
demonstrated the eﬀectiveness of externally applied electrical
ﬁelds in treating melanomas,42 enhanced drug inhibitory
eﬀects43 and tumors.44 Therefore, it is believed that the
electrical ﬁelds generated in situ with the combined use of SMF
and LIPUS can inﬂuence cancer cell activities and that the
mechanical stress generated due to LIPUS might also have a
synergetic role. In this investigation, we have focused to
evaluate the inﬂuence of LIPUS + SMF treatment on cancer
cell inhibition in the presence of MNP with anticancer drugs.
We have also made an attempt to understand the response of
two diﬀerent cancer cells to this external treatment.
Figure 1. (a) XRD analysis of MNP after calcination at 450 °C for 2 h. (b) Particle size analysis of MT + MNP. (c) FTIR spectra of (A) MNP (α-
Fe2O3), (B) MT + MNP (MT + α-Fe2O3), and (C) MT. (d) Thermogravimetric (TG) analysis (TGA) of (A) MNP, (B) MT + MNP, and (C) MT.
(e) Magnetic properties of (A) MNP and (B) MT + MNP. (f) Transmission electron microscopy analysis of MT + MNP. (g) Release of MT from
MT + MNP in phosphate-buﬀered saline (PBS, pH 7.4).
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2. RESULTS
2.1. Characteristics of MNP and Methotrexate (MT) +
MNP. The X-ray diﬀraction (XRD) analysis of MNP, presented
in Figure 1a, revealed all peaks corresponding to α-Fe2O3
(JCPDS no. 24-0072). No other phases were observed in the
calcined MNP. The crystallite size of the MNP calculated using
the Scherrer formula was 25 nm, while the particle size of MT +
MNP determined using the dynamic laser scattering technique
was found to be 61 nm (Figure 1b). The ζ potential of MT +
MNP was 50 mV, which signiﬁes its stability in suspension for
use as DDS. From the Fourier transform infrared (FTIR)
spectra, two broad peaks at 555 and 463 cm−1 were identiﬁed
for MNP (Figure 1c-A), which correspond to Fe−O stretching
and bending vibration modes of α-Fe2O3, respectively.
45 The
presence of a band at 1663 cm−1 is attributed to CO double
bond and C−O stretching vibration.46 The absorption band of
MT + MNP at 1385 cm−1 (Figure 1c-B) indicates high
intensity of nitrate (NO3
−) anions in their structure, which is an
indication of MT adsorption on the surface of MNP. This is
further corroborated by the absorption band in the broad range
of 3400 cm−1, which can be due to the stretching vibration of
structural hydroxyl groups of surface-adsorbed water on MT +
MNP.
During thermogravimetric analysis, the mass loss up to 250
°C in MT + MNP (Figure 1d-B) was due to the removal of
loosely bound water from the powder. The decomposition
between 220 and 400 °C was attributed to the decomposition
of adsorbed nitrate ions from MT and dehydroxylation of the
powder. The total mass loss of MNP was very low, up to 1000
°C (2.92%, Figure 1d-A). In the case of MT + MNP, it was
51.82% (Figure 1d-B), in which the initial mass loss, until 425
°C, was because of the water molecules of MNP. On the basis
of thermogravimetric analysis, the immobilization of MT on
MNP was estimated to be 48.82%. The magnetic behaviors of
MNP and MT + MNP, shown in Figure 1e-A,e-B, respectively,
demonstrate that both MNP samples exhibit weak ferromag-
netic behavior with a slight paramagnetic behavior. The
saturation magnetization of MNP was found to be higher
(0.62 emu/g) than that of MT + MNP with a saturation
magnetization of 0.27 emu/g. The decrease in the magnet-
ization of MT + MNP could be due to the adsorption of a large
amount (48.82%) of MT on its surface. The presence of
diamagnetic coating or material on MNP can decrease the
magnetic moment and therefore result in low magnet-
ization.47−49
As shown in Figure 1f, the MT + MNP powder appears to
have an average size of ∼50 nm. Figure 1g shows cumulative
release of MT from MT + MNP in PBS at pH 7.4. The initial
burst release of 80 wt % of MT during 8 h incubation was due
to desorption of the strained MTX molecule bound to MNP.
Cumulative release kinetics of MT from MNP was ﬁtted into
the Korsmeyer−Peppas model,50 following X = k(t − α)n,
where X, t, k, α, and n are the drug release (%), release time,
kinetics constant, modiﬁed parameter, and an exponent,
respectively.50 The exponent n (apparently R2) is normally
used to describe diﬀerent release mechanisms. The value of
exponent n was estimated to be 0.88, which indicates that the
release behavior of MT from MT + MNP is predominantly
diﬀusion-controlled.
2.2. Inﬂuence of LIPUS + SMF Treatment on Cancer
Cell Proliferation. Initially, proliferation of HCT116 and
HepG2 cells was assessed using 30 mW/cm2 LIPUS and its
combination with 3.5 and 150 mT SMF, and the results are
presented in Figure 2a,d, respectively. The proliferation of
HCT116 cells marginally reduced when exposed to LIPUS
during the ﬁrst 24 h (Figure 2a) and the cell proliferation
decreased at later culture durations. A signiﬁcant amount of cell
inhibition was observed when LIPUS was used in the presence
Figure 2. (a) HCT116 cell proliferation under 15 min/day treatment of 30 mW/cm2 LIPUS (L), 3.5 mT SMF (L + M3.5), and 30 mW/cm2 LIPUS
+ 150 mT SMF (L + M) (p < 0.05 between control and treated samples) (n = 12). (b) Dose response curve of MT on HCT116 cell viability and
determination of IC50 (n = 3). (c) HCT116 cell proliferation under 15 min/day treatment of L + M when the cells were exposed to MT and MT +
MNP (p < 0.05 between control and treated samples) (n = 12). (d) Proliferation assay of HepG2 cells under 15 min/day treatment of L + M3.5 and
L + M (p < 0.05 between control and treated samples) (n = 12). (e) Dose response curve of MT on HepG2 cell viability and determination of IC50
(n = 3). (f) Proliferation assay of HepG2 under 15 min/day treatment of L + M when the cells were exposed to MT and MT + MNP (p < 0.05
between control and treated samples) (n = 12).
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of 3.5 mT SMF (L + M3.5) at all culture durations, and with
150 mT SMF (L + M), further inhibition in HCT116 cells was
achieved. Almost 80% cell inhibition was observed after 72 h of
incubation with L + M, as shown in Figure 2a. A similar
inhibition was exhibited by HepG2 cells under these treatment
conditions (Figure 2d). The LIPUS treatment resulted in 5−
20% inhibition in these cells, which was increased to 50 and
70% in the presence of 3.5 mT SMF (L + M3.5) and 150 mT
SMF (L + M) at 72 h culture duration, respectively. Since both
cell lines (HCT116 and HepG2) showed maximum inhibition
with L + M treatment (30 mW/cm2 LIPUS + 150 mT SMF),
more detailed experiments were performed using this treat-
ment. The inﬂuence of MT concentration on the viability of
HCT116 and HepG2 cells is shown in Figure 2b,e, respectively.
Form these dose response curves, the half-maximal inhibitory
concentration (IC50) concentration of MT was determined to
be 10.04 ng/mL for HCT116 cells (Figure 2b) and 36 μg/mL
for HepG2 cells (Figure 2e). Further experiments in the
presence of MT drug were carried out using the IC50
concentration of respective cell lines.
The inﬂuence of diﬀerent treatment conditions on the
proliferation of HCT116 cells is shown in Figure 2c. The cell
proliferation decreased with culture duration under all
treatment conditions. However, the severity of cell inhibition
was highest with MT + MNP + L + M treatment. During the
initial 24 h, the inhibition of HCT116 cells was 30% with the
bare drug (MT), which increased to 50% with L + M treatment
(MT + L + M). Further enhancement in the cellular inhibition
Figure 3. (a−d) Gated HCT116 cell population in diﬀerent phases after 72 h of incubation (n = 6): (a) control (without MT); (b) MT-treated; (c)
MT + L + M-treated; and (d) MT + MNP + L + M-treated. (e−h) HepG2 cell-cycle assessment showing gated cell population in diﬀerent phases
after 72 h incubation (n = 6): (e) control (without MT); (f) MT-treated; (g) MT + L + M-treated; and (h) MT + MNP + L + M-treated.
Figure 4. (a−d) Apoptosis analysis of HCT116 cells after 72 h incubation (n = 6): (a) control (without MT); (b) MT-treated; (c) MT + L + M-
treated; and (d) MT + MNP + L + M-treated. (e−h) Apoptosis of HepG2 cells after 72 h incubation (n = 6): (e) control (without MT); (f) MT-
treated; (g) MT + L + M-treated; and (h) MT + MNP + L + M-treated.
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(60%) was achieved with MT + MNP + L + M, where the drug
was delivered using MNP. After 72 h of culture, the MT +
MNP + L + M treatment restricted the HCT116 cells to ∼14%.
Compared to MT, up to 30 and 36% increase in the cellular
inhibition were recorded with MT + L + M and MT + MNP +
L + M treatments, respectively, at 72 h culture. The diﬀerences
in cell proliferation were marginal between MT + L + M and
MT + MNP + L + M.
The results of similar proliferation assay experiments
performed with HepG2 cells are shown in Figure 2f. It appears
that the bare drug (MT) is relatively less eﬀective in inhibiting
HepG2 cells compared to HCT116 cells (Figure 2c) during the
ﬁrst 48 h of incubation, and at 72 h, both cells showed similar
amounts of proliferation. The L + M treatment was found to
aid HepG2 cell inhibition in the presence of MT (MT + L +
M). However, after 72 h incubation, the maximum proliferation
of HepG2 cells (40%, Figure 2f) could not match with
HCT116 cells, which showed 20% under identical treatment
conditions (Figure 2c). The MT + MNP + L + M treatment
showed strong inﬂuence on HepG2 cells with 17% proliferation
at the end of 72 h culture, and these cells showed relatively
more inhibition during the ﬁrst 48 h of culture compared to
HCT116 cells.
2.3. Eﬀect of LIPUS + SMF Treatment on Apoptosis
and Cell Cycle. The results of cell-cycle analysis performed on
two cancerous cell lines are presented in Figure 3. In both cell
lines, the population of cells in the S phase increased in the
presence of anticancer drug (MT) compared to the control
group (Figure 3a,e), which is in line with the known blocking
eﬀect of MT drug.51 The cell transition from the S to G2 phase
was found to be signiﬁcantly reduced (>67% of cells in the S
phase, p < 0.05 in Figure 3c) with MT + L + M treatment. No
cells were observed in the G2 phase when HCT116 cells were
treated with MT + MNP + L + M, as shown in Figure 3d. Cell-
cycle analysis revealed that the HepG2 cells are more sensitive
to L + M treatment, as shown in Figure 3g−h. With MT + L +
M treatment, majority of the cells were restricted to the G1
phase, followed by the S phase (Figure 3g). Interestingly, 100%
cell blockage to the G1 phase occurred in HepG2 cells with
MT + MNP + L + M treatment. These observations
demonstrate that the eﬃciency of MT and MT + MNP can
be increased with LIPUS + SMF treatment, more eﬀectively in
HepG2 cells than in HCT116 cells.
The apoptosis assay of HCT116 shows 50% necrosis in the
presence of MT (Figure 4b), which is signiﬁcantly higher than
that of control samples (20%, Figure 4a). However, Figure 4c
shows that the cell response appears to be diﬀerent when the
MT was added in the presence of L + M treatment (MT + L +
M), where a signiﬁcant reduction in necrosis was observed.
Moreover, the concentration of apoptotic cells was also
increased to 29% from 6% in MT treatment (Figure 4b).
Interestingly, when MT + MNP was administered along with L
Figure 5.Measured intracellular ROS in terms of ﬂuorescence intensity. (a) HCT116 cells treated with MT, MT + L + M, and MT + MNP + L + M.
(b) HepG2 cells treated with MT, MT + L + M, and MT + MNP + L + M. The control group had no treatment.
Figure 6. Changes in the membrane potential determined using voltage-sensitive bis(1,3-dibutylbarbituric acid)trimethineoxonol (DiBAC4(3)) dye
(n = 6): (a) HCT116 cells and (b) HepG2 cells.
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+ M treatment (Figure 4d), the apoptosis was further increased
to 32%. The L + M treatment, with and without MNP, along
with MT gradually increased the cellular transition from early
to late apoptosis compared to bare MT. The response of
HepG2 cells to these treatments was also found to be similar to
HCT116 cells (Figure 4e−g). However, the amount of
apoptotic and necrotic cells was high in HepG2 cells compared
to HCT116 cells with MT + MNP + L + M treatment.
2.4. Intracellular ROS and Membrane Potential
Changes. It is known that the oxidative stress, which is
related to elevated intracellular levels of reactive oxygen species
(ROS), can damage cell structure, DNA, proteins, and lipids,
leading to cell death. Therefore, we have measured the
oxidative stress generated under diﬀerent treatment conditions
in terms of ROS. As the ROS production can be directly related
to the damage of the cellular structure, DNA, and proteins/
lipids, the amount of ROS production in HCT116 and HepG2
cells was measured under diﬀerent conditions. The results
presented in Figure 5a indicate that the ROS intensity increased
(164%) from 75 to 198 when the HCT116 cells were treated
with MT and the intensity drastically increased to 695 with L +
M treatment, almost 250% increase in the ROS production.
Further increase in the intensity up to 763 was recorded with
MT + MNP + L + M treatment. In case of HepG2 cells, the
ROS intensity increased gradually from 491 for MT to about
1981 for MT + MNP + L + M treatment (Figure 5b).
Compared to HCT116 cells, the MT + L + M and MT + MNP
+ L + M treatments resulted in 95 and 160% more ROS
production in HepG2 cells, respectively.
The change in the cell membrane potential of HCT116 cells
under diﬀerent treatment conditions is shown in Figure 6a,
where the peaks of treated cells shifted toward left, compared to
the control group, indicating that they are hyperpolarized.
Hyperpolarization can result in increased transmembrane
transport of several ions, followed by cell death.52−54 The
severity of hyperpolarization was found to be maximum in
HCT116 cells with MT + MNP + L + M treatment. HepG2
cells exhibited more gradual increase in the hyperpolarization
with MT, MT + L + M, and MT + MNP + L + M treatment, as
shown in Figure 6b. Maximum hyperpolarization was achieved
with MT + MNP + L + M treatment, followed by MT + L + M
and minimum with MT treatment.
2.5. Fluorescence Microscopy. The initiation of changes
in the nucleus of HCT116 and HepG2 cells due to L + M
treatment was observed using 4′,6-diamidino-2-phenylindole
(DAPI) staining after 24 h culture. The morphology of DAPI-
stained cell nuclei is presented in Figure 7a. It was observed
that the MT-treated cells showed relatively more chromatin
condensation in HCT116 cells compared to HepG2 cells,
indicating better eﬀect of anticancer drug on HCT116 in terms
of apoptosis, as chromatin condensation is the primary
indication of apoptosis. Chromatin condensation was prom-
inent in both cells under MT + L + M treatment. Finally, the
MT + MNP + L + M treatment appears to induce complete
protein denaturization and nucleus damage in both HCT116
Figure 7. (a) Morphology of DAPI-stained HCT116 and HepG2 cell nuclei under diﬀerent treatment conditions after 72 h incubation. The arrows
indicate the cells with damaged cell nucleus. (b) Quantiﬁcation of HCT116 cell damage in terms of nucleus intensity in ﬂuorescence images. (c)
Changes in the ﬂuorescence nucleus intensity of HepG2 cells under diﬀerent treatment conditions.
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and HepG2 cells at 72 h incubation. The degree of nucleus
damage was quantiﬁed by analyzing the nucleus intensity of
ﬂuorescence images using ImageJ software and compared with
that of control group.55 The results, shown in Figure 7b,
revealed almost fourfold increase in the damage of HCT116
cells after MT + MNP + L + M treatment. Similarly, in HepG2
cells, the maximum cellular damage (3.71-fold) was achieved
with MT + MNP + L + M treatment. The morphology and
features of cell nucleus show damaged cell nucleus, which is an
indication of apoptosis56 that can directly induce cellular
inhibition and thus provide overall improvement in the
treatment eﬃcacy.
2.6. Inﬂuence of LIPUS + SMF Treatment on Healthy
Cells. The proposed L + M treatment was found to have a
strong inﬂuence on cancer cell proliferation, as shown in Figure
2, but the potential negative eﬀect of this treatment on normal/
healthy cells is not known. Therefore, a similar cell proliferation
assay was performed on MC3T3 (mouse pre-osteoblast) cells.
The results (Figure 8) show that only LIPUS (L: 30 mW/cm2)
had very little inhibiting eﬀect on the proliferation during the
initial 24 h and the proliferation increased signiﬁcantly after 48
and 72 h culture. The SMF (M: 150 mT) enhanced the cell
proliferation at all culture durations. The L + M treatment had
a maximum positive inﬂuence on MC3T3 cell proliferation,
demonstrating its nontoxic eﬀect on healthy cells.
3. DISCUSSION
In spite of signiﬁcant research on DDS-based cancer treatment,
its limitations, such as poor stability, reunion of nanosized DDS
due to high surface area, limitation in target-site speciﬁcity for
accumulation and delivery of eﬀective biomolecules, high cost
due to complex synthesis procedures, and poor invasiveness
into tumor microenvironment, result in low treatment
eﬃciency.57−59 Therefore, newer adjuvant therapies that can
enhance the overall eﬃciency of the current DDS are required.
The present MT + MNP-based DDS with diﬀusion-controlled
drug release at physiological pH shows acceptable conditions of
release environment.60 In this investigation, with the use of 30
mW/cm2 LIPUS in the presence of 150 mT SMF (L + M), 15
min/day, the in vitro DDS inhibition eﬀectiveness has been
enhanced by 35% in colon (HCT 116) and hepatocellular
(HepG2) carcinoma cells after 72 h incubation. The use of L +
M treatment can generate a noninvasive synergy between the
mechanical stress generated by LIPUS61 and local electrical
ﬁelds22 generated by combinational exposure of LIPUS and
SMF, which are believed to alter the activities of these cells by
hyperpolarizing the cell membrane,41 and production of large
amounts of ROS resulting in observed cellular inhibition. As the
cancer cells are known for their rapid proliferation assisted by
their depolarized cellular membrane,62 the LIPUS + SMF
treatment-induced hyperpolarization destabilized the cell
structure and increased the cellular apoptosis. The hyper-
polarization of the cellular membrane results in an intra- and
extracellular ionic imbalance of cancer cells via increased intake
of anticancer drug (MT) or drug-loaded MNP (MT + MNP).
Hyperpolarization via MT and MT + MNP internalization after
exposure to LIPUS + SMF indicate a potential release of K+
ions from cell interior or ingress of more Cl− ions into the cells,
leading to changes in the ionic gradient across the cell
membrane. This imbalance of ionic ﬂow changes the cell
membrane permeability,54 which directly leads to alteration of
cellular conformation as well as restrict the DNA synthesis of
cancer cells. Furthermore, the signiﬁcantly high production of
ROS in HepG2 cells compared to HCT116 cells clearly
indicates that the treatment has varying inﬂuence depending on
the cell type and therefore the treatment conditions must be
optimized to treat diﬀerent cancer types. The diﬀerences in
treatment responses by diﬀerent cells could be attributed to the
variations in their characteristics, such as cell membrane
potential.63
The cell-cycle restriction (blockage in the S phase or G1→ S
phase transition) increased signiﬁcantly due to the application
of LIPUS + SMF in the presence of MT + MNP (no cells in
the G2 phase for HCT116 and no cells in the S and G2 phases
for HepG2). These results suggest that the L + M treatment
creates hindrance in DNA synthesis, leading to cell-cycle arrest
as a result of altered/destabilized cell membrane potential and
enhanced intake of MT and MT + MNP by the cancer cells.
Further, cell apoptosis analysis demonstrates that LIPUS +
SMF treatment can accelerate the cellular activities of HCT116
and HepG2 cells, which is evinced by increase in the apoptotic
cells (46% for HepG2 cells and 33% for HCT116 cells). A
signiﬁcant increase in the late apoptotic cell population of
HepG2 cells (35%) also signiﬁes loss of plasma membrane
integrity and DNA fragmentation in these cells. Necrosis is
caused by factors external to the cell or tissue, such as infection,
toxins, or trauma, which result in the unregulated digestion of
cell components. In contrast, apoptosis is a naturally occurring
programmed and targeted cause of cellular death. One
important ﬁnding in this analysis has been considerable
reduction in necrosis of cells with L + M treatment. It is
generally considered that necrosis is unprogrammed cell death
and therefore detrimental to the biological system. Although
late apoptotic and necrotic cells have permeabilized cell
membranes, due to diﬀerent events associated with their
membrane damage, their response to clearance/removal signals
would be diﬀerent. Therefore, removal of necrotic cells from
the system would be relatively more diﬃcult than apoptotic
cells.64 The decrease in necrosis with L + M treatment is thus
beneﬁcial for cancer treatment with potentially low side eﬀects.
It is also evident that the synergetic eﬀect of LIPUS + SMF
treatment resulted in overproduction of ROS in both cell lines.
The interaction of LIPUS + SMF treatment with polar and
charged ionic elements of cells produced large amounts of
ROS, which is a proinﬂammatory factor of cellular component
responsible for cancer cell apoptosis.22,56,65 Excessive produc-
tion of ROS damages the DNA of cancer cells through the
Fenton reaction23 and results in oxidative stress accelerating
apoptosis. It has been observed that the ion channels of cancer
Figure 8. Proliferation of MC3T3 cells (n = 3) exposed to LIPUS (30
mW/cm2) (L), SMF (150 mT) (M), and their combination (L + M)
(p < 0.05 between untreated and treated samples).
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cells are damaged leading to changes in their morphology and
apoptosis due to excessive ROS production.23
We hypothesize that application of 30 mW/cm2 LIPUS +
150 mT SMF can generate electrical and mechanical stimuli in
situ during the treatment,22,42 which are believed to be
responsible for the observed enhancement in cancer cell
inhibition with this treatment. Under present experimental
conditions, the mechanical stimulus generated by LIPUS at the
cell/soft tissue was estimated ( = ·p I Z , where p is the
eﬀective pressure (Pa), I is the intensity of ultrasound (W/
cm2), and Z is the acoustic impedance of the cell or soft tissue
(kg/(m2 s))) to be between 20 and 22 kPa. The estimated
electrical ﬁeld (E) ( = · ·( ) ( )E BC pZ1 , where C is the velocity of
light (m/s), B is the magnetic ﬁeld strength (G); E is measured
in electrostatic units esu (1 esu = 300 V/cm)) would be
between 19 and 23 μV/cm. These in situ generated physical
stimuli would have physically deformed (elastic or plastic) the
cells/tissues, which can be seen from the hyperpolarization of
the cell membranes. The intake of drug can be increased with
the potential formation of stomas or lacunars in the cell
membranes due to mechanical stress generated via LIPUS.66−68
Moreover, the pressure induced by LIPUS has been
demonstrated to induce ∼50 μm/s micromotions in the
tissues,69 which is believed to aﬀect the membrane stability. As
with externally applied electrical ﬁelds,70 the in situ generated
electrical ﬁelds, although small, would have negatively regulated
the cancer cellular activities.40 Interestingly, the L + M
treatment was demonstrated to be safe for healthy cells
(MC3T3) presumably due to diﬀerences in cell characteristics
between cancer and healthy cells. However, toxicity due to the
accumulation of these MNP is an important concern, which can
be reduced by guiding the MNP using focused magnetic
ﬁelds.16 Another approach for targeting MNP with minimal
accumulation involves functionalization of these NPs with
tissue-speciﬁc adhesion molecules (homing receptors).71,72
These two approaches are to be examined in conjunction
with current LIPUS + SMF treatment to realize the full
potential of this noninvasive treatment.
4. CONCLUSIONS
Detailed in vitro experimental results demonstrate that the
proposed noninvasive LIPUS + SMF treatment can stimulate
cancer cell inhibition three times better than bare drug or DDS.
The treatment appears to be relatively more eﬀective for early-
time inhibition of HepG2 cells than HCT116 cells in the
presence of MT + MNP. The production of ROS is also higher
in HepG2 cells than in HCT116 cells. The treatment
signiﬁcantly reduced the amount of necrosis and induced
hyperpolarization in both cancer cell lines. The in situ
generated mechanical and electrical stimuli are thought to be
responsible for the observed increase in cancer cellular
inhibition via altered cell membrane characteristics. Since the
treatment did not have any inhibitory eﬀect on healthy cells, it
is believed to have strong application potential to inhibit a
variety of other cancer cell lines. The present in vitro results can
form the basis for further investigations including targeting
speciﬁc tissues, using homing molecule functionalized MNP
and magnetic guidance, and in vivo trials to assess the
eﬀectiveness of this treatment.
5. MATERIALS AND METHODS
Deionized and decarbonized ultrapure water (Millipore, speciﬁc
resistivity: 18 MΩ, conductivity: 0.05 μS/cm) was used in all
preparations, and the chemicals used in this study were
Fe(NO3)3·9H2O (99.0%, Merck), NH2OH (99.0%, Merck),
urea (99.0%, Merck), NH4OH (99.5%, Sigma-Aldrich), and
methotrexate (99.5%, Sigma-Aldrich).
5.1. Synthesis and Characterization of MNP (α-Fe2O3)-
and Methotrexate-Loaded MNP (MT + MNP). Fe2O3
nanoparticles (MNP) were synthesized following precipitation
route using ammonia and urea. In a typical synthesis, 20 cc of
ammonia solution (25%) was added dropwise to 20 cc of 0.1 M
Fe(NO3)3·9H2O solution at 90 °C and stirred for 1 h. A ﬁne
precipitate was obtained, which was ﬁltered and washed three
times with deionized water. Then, the water was removed with
acetone (dehydrating agent), followed by overnight drying of
the precipitate at 60 °C and calcination at 450 °C for 2 h. Since
the primary focus of this investigation has been to evaluate the
inﬂuence of LIPUS + SMF treatment on cancer cell inhibition,
we have intentionally used weak ferromagnetic/paramagnetic
nanoparticles to eliminate or reduce the accumulation of MNP
during this treatment. Further, the use of magnetic ﬁeld is to
generate the proposed electrical ﬁeld/charge noninvasively in
the presence of LIPUS. In fact, in our earlier investigation, we
have used nonmagnetic NPs to evaluate the inﬂuence of LIPUS
+ SMF treatment,73 and in this investigation, we attempted to
analyze the eﬀect of magnetic carriers.
For anticancer drug loading, 1 g of calcined MNP was
suspended in 5 cc of ethanol with 1 g of methotrexate (MT)
and the solution was sonicated for 15 min. The prepared
solution was aged overnight to evaporate the ethanol and
obtain drug-loaded MNP (MT + MNP). For drug release
study, 30 mg of MT + MNP was dispersed in 30 mL of freshly
prepared PBS (pH 7.4) and was used as the analyte. Then, at
speciﬁc time intervals, an aliquot of 3 mL was removed from
the main stock and the optical density was determined using a
UV−visible spectrophotometer (Lambda 35, PerkinElmer).
Initially, a calibration curve was prepared to calculate the
concentration of drug released into PBS at speciﬁc incubation
time.
Powder X-ray diﬀraction (XRD) analysis of MNP was
performed using an X’Pert Pro MPD diﬀractometer (PAN-
alytical, Almelo, the Netherlands) in the 2θ range between 5
and 70°. The particle size of MNP and MT + MNP was
measured by dynamic light scattering (Malvern, Germany)
using dilute suspensions of powder in water. The ζ potential
was determined using a Zetasizer (Zetasizer 2000, Malvern,
Germany) with a dilute suspension of the powder in PBS
having pH 7.4. The morphology of MNP and MT + MNP was
studied using a transmission electron microscope (TECHNAI
G2 30ST, and FEI). To identify the absorption bands of MT in
MT + MNP, Fourier transform infrared (FTIR) spectra of the
powder was recorded at room temperature using the KBr
(Sigma-Aldrich, ≥99%) pellet method (sample: KBr = 1:100)
using a spectrophotometer (Spectrum100, PerkinElmer) in the
400−4000 cm−1 range with an average of 50 scans. The
magnetic properties of the powder (∼0.2 g) were determined
using a vibrating sample magnetometer (VSM, LakeShore7407)
under a maximum ﬁeld of 15 kOe at room temperature.
Thermogravimetric analyses (TGA)−diﬀerential thermal anal-
ysis (DTA) of the powder were carried out between 25 and
1000 °C at a heating rate of 10 °C/min in air to estimate the
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absorption of MT on MNP using a TGA/DTA instrument
(NETZSCH STA 409 CD, Germany).
5.2. Cytotoxicity Assay. 5.2.1. Cell Culture and IC50 of
MT. Human colon carcinoma (HCT116) and hepatocellular
carcinoma (HepG2) (ATCC, Rockville, MD) cells were
routinely cultured separately in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) (Invitrogen, Carlsbad) supplemented with
10% heat-inactivated fetal bovine serum, 1 U/mL penicillin G,
and 1 mg/mL streptomycin, in a T75 ﬂask in a CO2 incubator
(ESCO, Singapore) at 37 °C with 5% CO2. It was distributed
using a six-well plate after full conﬂuency. The half-maximal
inhibitory concentration (IC50) of MT was evaluated at various
concentrations in the range of 5−100 ng/mL with 10 mg/mL
MT stock solution in dimethyl sulfoxide (DMSO, Sigma-
Aldrich, India). After the cells were plated at 2 × 104/well
density, they were incubated at 37 °C in a CO2 incubator for 24
h to allow cell adhesion and the incubation was continued for a
total duration of 72 h after the addition of MT (n = 3). After 72
h incubation, the MTT assay was performed by adding 10 μL of
3-(4,5-dimethylthiazole-2-yl)-2,5-phenyltetrazolium bromide
(MTT) reagent with a concentration of 1 mg/mL (Sigma-
Aldrich) in a 1:9 ratio (MTT/DMEM) to all wells and
incubated in the dark for 4 h at 37 °C. Then, the solution was
removed and 100 μL of DMSO was added to each well. The
absorbance of the solution was measured at 550 nm in an
ELISA reader (Bio-Rad) to generate the dose response curve.
The IC50 was determined from the dose response curve.
5.2.2. Cell Proliferation Assay. Both HCT116 and HepG2
cells were subcultured in 35 mm Petri plates at a density of 2 ×
104 and incubated overnight. Then, MT or MT + MNP was
added at desired concentrations (MT at IC50 concentration for
each cell line and MNP including MT at 46 μg/mL for
HCT116 and 73 μg/mL for HepG2), followed by exposure to
3.5 and 150 mT SMF (⌀ 30 mm, 5−6 mm thick NdFeB
permanent magnets) and LIPUS (probe ⌀ 22.22 mm, 30 mW/
cm2, 1.5 MHz, 200 μs pulse width at 1 kHz). The treatment
(LIPUS + SMF) time was 15 min/day, and the MTT assay was
performed after 24, 48, and 72 h incubation. A similar
proliferation assay was also carried out using mouse pre-
osteoblast cells (MC3T3) (ATCC, Rockville, MD) to assess
the eﬀect of LIPUS + SMF treatment on these healthy cells.
The details of sample notations used in the present
investigation are presented in Table 1.
5.3. Apoptosis and Cell-Cycle Analysis. To analyze the
inﬂuence of diﬀerent treatments on the cellular activities of
HCT116 and HepG2 cells, cell-cycle analysis was performed
using Cycletest PLUS DNA reagent kit (BD Cat no: 340242).
The amount of cell apoptosis was determined by Annexin V/
propidium iodide double-staining kit (BD Biosciences, Cat no:
556570). For the analysis, 1 × 105 treated cells were trypsinized
and washed with 1× PBS and the suspended pellet was
analyzed using a ﬂow cytometer (CyFlow Cube 6, SysmexPar-
tec GmbH, Germany). Both analyses were performed after 72 h
culture duration.
5.4. Measurement of Reactive Oxygen Species (ROS)
and Cell Membrane Potential. After desired treatment, the
cells (1 × 105) were trypsinized, washed with 1× PBS, and
resuspended in 1 mL of 1× PBS to detect ROS using standard
detection assay kit (ab186029, Abcam, India). The intensity of
2′,7′-dichloroﬂuorescin diacetate was detected using a ﬂow
cytometer at 650 nm. Plasma membrane potential changes
were measured using bis(1,3-dibutylbarbituric acid)-
trimethineoxonol (DiBAC4(3) dye; Invitrogen, Carlsbad,
CA). To measure the membrane potential, trypsinized cells
were incubated in 100 nM DiBAC4(3) dye for 10 min in the
dark and then the mean ﬂuorescence intensity was measured
using a ﬂow cytometer at 488 nm.
5.5. Fluorescence Microscopy. Qualitative analysis of
treated cancer cells in terms of their nucleus and nuclear
membrane structures was carried out by DAPI (Cat no: D1306,
Thermo Fisher) staining. The cells were plated at a density of 3
× 103 in a 35 mm Petri plate. After desired culture duration (72
h), the cells were rinsed with PBS three times, followed by
ﬁxing for 10 min in 3.7% formaldehyde. The cells were
permeabilized by immersing in 0.2% Triton X-100 for 5 min
and incubating the cells for 1−5 min at room temperature in
diluted DAPI solution (1:5000). After aspirating the labeled
solution, the cells were rinsed three times in PBS. Counter-
staining was performed by adding 2.5 μg/mL ﬂuorescein
isothiocyanate to each well and kept for 5 min and then washed
three times using PBS. Finally, the cells were imaged using a
ﬂuorescence microscope (Olympus BX51TRF, Tokyo, Japan).
5.6. Statistical Analysis. The data obtained in cell
proliferation, cell apoptosis, cell cycle, ROS, and membrane
potential measurements were statistically analyzed using the
Student t-test and p < 0.05 was considered statistically
signiﬁcant.
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